SANION Stock Overview
A clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, Germany, Denmark, the United Kingdom, and Mexico.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Saniona AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr3.89 |
| 52 Week High | kr12.44 |
| 52 Week Low | kr1.74 |
| Beta | 1.03 |
| 1 Month Change | 115.87% |
| 3 Month Change | 99.69% |
| 1 Year Change | -64.31% |
| 3 Year Change | -79.31% |
| 5 Year Change | -79.18% |
| Change since IPO | -24.47% |
Recent News & Updates
Recent updates
Saniona (STO:SANION) Is Making Moderate Use Of Debt
Nov 29
Is Saniona (STO:SANION) Using Too Much Debt?
Aug 16Is Saniona (STO:SANION) Using Too Much Debt?
Mar 17Need To Know: Saniona AB (publ) (STO:SANION) Insiders Have Been Buying Shares
Feb 10What Type Of Shareholders Make Up Saniona AB (publ)'s (STO:SANION) Share Registry?
Jan 06Is Saniona (STO:SANION) Using Too Much Debt?
Dec 02Shareholder Returns
| SANION | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 26.9% | -2.6% | -2.1% |
| 1Y | -64.3% | 3.0% | 11.2% |
Return vs Industry: SANION underperformed the Swedish Biotechs industry which returned 4.5% over the past year.
Return vs Market: SANION underperformed the Swedish Market which returned 12.8% over the past year.
Price Volatility
| SANION volatility | |
|---|---|
| SANION Average Weekly Movement | 10.9% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in SE Market | 12.7% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: SANION's share price has been volatile over the past 3 months.
Volatility Over Time: SANION's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 23 | Thomas Feldthus | www.saniona.com |
Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, Germany, Denmark, the United Kingdom, and Mexico. It also develops medicines modulating ion channels. The company’s products include Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity; and Tesomet, an oral investigational therapy, which is Phase 2b clinical trial for the treatment of hypothalamic obesity and Prader-Willi syndrome.
Saniona AB (publ) Fundamentals Summary
| SANION fundamental statistics | |
|---|---|
| Market cap | kr432.72m |
| Earnings (TTM) | -kr83.30m |
| Revenue (TTM) | kr20.71m |
20.9x
P/S Ratio-5.2x
P/E RatioIs SANION overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SANION income statement (TTM) | |
|---|---|
| Revenue | kr20.71m |
| Cost of Revenue | kr5.38m |
| Gross Profit | kr15.34m |
| Other Expenses | kr98.64m |
| Earnings | -kr83.30m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 29, 2024
| Earnings per share (EPS) | -0.75 |
| Gross Margin | 74.05% |
| Net Profit Margin | -402.20% |
| Debt/Equity Ratio | 144.9% |
How did SANION perform over the long term?
See historical performance and comparison